


Searching News Database: Apeiron Biologics
HSMN NewsFeed - 8 Jul 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
